Sign In
Buy KOD
$33.87
+0.655 (+1.97%)
At Close: Jun 03, 2026
Kodiak Sciences scraps development of eye disorder drug
06:38am, Monday, 24'th Jul 2023
Kodiak Sciences Inc decided to discontinue development of its experimental drug to treat a type of eye disorder, sending its shares tumbling 40% in premarket trading on Monday.
Kodiak Sciences stock plunges into record-low territory after decision to discontinue wet AMD treatment
06:36am, Monday, 24'th Jul 2023
Shares of Kodiak Sciences Inc. KOD, +2.97% plummeted 56.9% into record-low territory, and to pace all premarket declines, after the California-based biotechnology company said it decided to discontinu
Why Is Kodiak Sciences Inc. (KOD) Up 62.9% Since Last Earnings Report?
12:43pm, Wednesday, 14'th Jun 2023
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock?
Kodal Minerals says Bouguoni financing date now end June, hits more high-grade lithium
02:42am, Wednesday, 31'st May 2023
Kodal Minerals and Hainan Mining have agreed to a long stop extension until 30 June 2023 to ratify the financing package for the Bougouni lithium project in southern Mali. Bernard Aylward, Kodal's ch
Kodiak Sciences to Present at Upcoming Investor Conferences
04:15pm, Tuesday, 30'th May 2023
PALO ALTO, Calif., May 30, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to
Kodiak (KOD) Advances With Tarcocimab Amid Stiff Competition
12:25pm, Tuesday, 30'th May 2023
Kodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications. However, competition in the market and the lack of other candidates in the pipeline are concerns.
Kodiak's (KOD) Q1 Earnings Miss, Pipeline in Focus, Stock Up
09:07am, Tuesday, 16'th May 2023
Despite poor first-quarter performance, Kodiak (KOD) stock rises 13% on the strong pace of the tarcocimab clinical programs.
Why Is Kodiak Sciences Inc. (KOD) Down 26.3% Since Last Earnings Report?
12:56pm, Thursday, 27'th Apr 2023
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock?
Kodiak (KOD) Treats First Patient in Diabetic Macular Edema Study
02:28pm, Tuesday, 04'th Apr 2023
Kodiak (KOD) has its first patient in the early-stage study of KSI-501 for treating retinal diseases.
Kodiak Sciences (KOD) Shares are Up 26% in a Week: Here's Why
12:55pm, Monday, 03'rd Apr 2023
Shares of Kodiak Sciences (KOD) shot up 26% in the last week after the company announced remaining on track with ongoing studies in its fourth-quarter and full-year 2022 earnings report.
Kodiak Sciences Inc. (KOD) Up 1% Since Last Earnings Report: Can It Continue?
12:48pm, Friday, 09'th Dec 2022
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock?
Kodiak: Turnaround Strategy Has Shown Life Thus Far
01:17pm, Monday, 14'th Nov 2022
Primary endpoint of phase 3 BEACON study, using tarcocimab tedromer for the treatment of patients with macular edema due to retinal vein occlusion, was met. Four additional studies are expected to hav
Kodiak Sciences' (KOD) Q3 Earnings Beat, Eye Candidate in Focus
03:48pm, Thursday, 10'th Nov 2022
Kodiak Sciences (KOD) reports a narrower-than-expected loss for the third quarter of 2022. The focus is on the lead candidate, KSI-301, developed for treating various retinal vascular diseases.
Why Is Kodiak Sciences Inc. (KOD) Down 23.8% Since Last Earnings Report?
12:47pm, Thursday, 08'th Sep 2022
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock?
Kodiak Sciences (KOD) Rises 60% in Past 3 Months: Here's Why
03:03pm, Friday, 26'th Aug 2022
Kodiak Sciences (KOD) has progressed well with the development of its lead pipeline candidate, tarcocimab, for treating various retinal vascular diseases.
